Form 4: Tyra Biosciences Director Acquires 37,200 Shares Through Option Grant

Director Susan Moran acquired 37,200 shares of Tyra Biosciences common stock through an option grant on May 7, 2024, at an exercise price of $17.94.

Summary

• On May 7, 2024, Susan Moran, a director of Tyra Biosciences, Inc. acquired 37,200 shares of common stock through an option grant.
• The exercise price of the option is $17.94 per share.
• The options vest monthly over a three-year period, starting May 7, 2024, contingent upon continuous service to the Issuer.
• The expiration date for the options is May 6, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by a director is generally viewed as a positive sign, but it's a routine transaction.

Positives

• A director's acquisition of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future stock performance.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates